Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2012 Filed Feb 2, 2012 20:46 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 33,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006946 · doc4.xml · derivative · entry 4 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vests in three equal annual installments as follows: 33,333 on February 1, 2011; 33,333 on February 1, 2012; and 33,334 on February 1, 2013. F1 · derivative.expiration_date: The Restricted Stock Units vests in three equal annual installments as follows: 33,333 on February 1, 2011; 33,333 on February 1, 2012; and 33,334 on February 1, 2013. Read SEC document |
| February 01, 2012 Filed Feb 2, 2012 20:46 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Tax withholdingCommon Stock | 11,338 | $39.74 | $450,572.12 |
DisclosureSEC source: 0001209191-12-006946 · doc4.xml · nonDerivative · entry 2 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,347 Read SEC document |
| February 01, 2012 Filed Feb 2, 2012 20:46 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006946 · doc4.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 21:35 UTC |
HANISH ARNOLD CChief Accounting Officer
|
GrantCommon Stock | 2,210 | $39.44 | $87,162.40 |
DisclosureSEC source: 0001209191-12-006102 · doc4.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,255 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:10 UTC |
ARMITAGE ROBERT ASr. VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 35,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006119 · doc4.xml · derivative · entry 4 ARMITAGE ROBERT A · CIK 0001233249 · Sr. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,297 Underlying: Common Stock · 35,297 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:10 UTC |
ARMITAGE ROBERT ASr. VP and General Counsel
|
GrantCommon Stock | 17,709 | $39.44 | $698,442.96 |
DisclosureSEC source: 0001209191-12-006119 · doc4.xml · nonDerivative · entry 1 ARMITAGE ROBERT A · CIK 0001233249 · Sr. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,756 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:13 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 31,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006122 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,768 Underlying: Common Stock · 31,768 shares Expires 2013-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:13 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 7,117 | $39.44 | $280,694.48 |
DisclosureSEC source: 0001209191-12-006122 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,012 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:17 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantCommon Stock | 10,719 | $39.44 | $422,757.36 |
DisclosureSEC source: 0001209191-12-006125 · doc4.xml · nonDerivative · entry 1 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,719 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:24 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 5,962 | $39.44 | $235,141.28 |
DisclosureSEC source: 0001209191-12-006128 · doc4.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,033 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:27 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GrantRestricted Stock Unit · Derivative | 132,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006130 · doc4.xml · derivative · entry 6 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,367 Underlying: Common Stock · 132,367 shares Expires 2013-02-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:27 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GrantCommon Stock | 59,601 | $39.44 | $2,350,663.44 |
DisclosureSEC source: 0001209191-12-006130 · doc4.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,864 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:29 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 44,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006132 · doc4.xml · derivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,122 Underlying: Common Stock · 44,122 shares Expires 2013-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 22,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,943 Underlying: Common Stock · 22,943 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 3,077 | $39.44 | $121,356.88 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,620 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,203 | $39.44 | $47,446.32 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,479 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:39 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 8,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006143 · doc4.xml · derivative · entry 4 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,825 Underlying: Common Stock · 8,825 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:39 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 3,843 | $39.44 | $151,567.92 |
DisclosureSEC source: 0001209191-12-006143 · doc4.xml · nonDerivative · entry 1 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,536 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:43 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 14,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006146 · doc4.xml · derivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 Underlying: Common Stock · 14,119 shares Expires 2013-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:45 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantRestricted Stock Unit · Derivative | 52,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006149 · doc4.xml · derivative · entry 5 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,947 Underlying: Common Stock · 52,947 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:45 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantCommon Stock | 25,573 | $39.44 | $1,008,599.12 |
DisclosureSEC source: 0001209191-12-006149 · doc4.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,573 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:48 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantCommon Stock | 6,948 | $39.44 | $274,029.12 |
DisclosureSEC source: 0001209191-12-006151 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,884 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:51 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 17,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006154 · doc4.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,649 Underlying: Common Stock · 17,649 shares Expires 2013-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:51 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
GrantCommon Stock | 4,686 | $39.44 | $184,815.84 |
DisclosureSEC source: 0001209191-12-006154 · doc4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,082 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:53 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantRestricted Stock Unit · Derivative | 17,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006156 · doc4.xml · derivative · entry 4 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,649 Underlying: Common Stock · 17,649 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:53 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantCommon Stock | 5,237 | $39.44 | $206,547.28 |
DisclosureSEC source: 0001209191-12-006156 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,869 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:58 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 3,600 | $39.44 | $141,984.00 |
DisclosureSEC source: 0001209191-12-006159 · doc4.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,888 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:58 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 11,884 | $39.44 | $468,704.96 |
DisclosureSEC source: 0001209191-12-006159 · doc4.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,384 Read SEC document |
| January 26, 2012 Filed Feb 2, 2012 23:45 UTC Amendment |
HANISH ARNOLD CChief Accounting Officer
|
GrantCommon Stock | 2,235 | $39.44 | $88,148.40 |
DisclosureSEC source: 0001209191-12-007171 · doc4a.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,280 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 1/30/2012; 25 shares were inadvertently omitted from the total. Read SEC document |
| January 26, 2012 Filed Feb 2, 2012 23:48 UTC Amendment |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,285 | $39.44 | $50,680.40 |
DisclosureSEC source: 0001209191-12-007174 · doc4a.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,561 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 1/30/2012; 82 shares were inadvertently omitted from the total. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2012 Filed Feb 3, 2012 00:09 UTC Amendment |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 11,883 | $39.44 | $468,665.52 |
DisclosureSEC source: 0001209191-12-007187 · doc4a.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,383 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 1/30/2012; a difference of 1 share was inadvertently reported. Read SEC document |
| December 30, 2011 Filed Jan 3, 2012 21:34 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 248 | $40.74 | $10,103.52 |
DisclosureSEC source: 0001209191-12-000424 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,788 Read SEC document |
| December 29, 2011 Filed Feb 16, 2012 20:00 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-010739 · doc5.xml · nonDerivative · entry 3 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,186 Read SEC document |
| December 20, 2011 Filed Feb 16, 2012 20:00 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-010739 · doc5.xml · nonDerivative · entry 2 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,206 Read SEC document |
| December 16, 2011 Filed Feb 16, 2012 20:00 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 40 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-010739 · doc5.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,226 Read SEC document |
| December 12, 2011 Filed Dec 14, 2011 16:21 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,787 | $39.10 | $226,271.70 |
DisclosureSEC source: 0001209191-11-061194 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,266 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.06 to $39.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2011 Filed Feb 3, 2012 00:19 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
GiftCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007195 · doc5.xml · nonDerivative · entry 2 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,799 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 06, 2011 Filed Feb 3, 2012 00:19 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
GiftCommon Stock | 1,244 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007195 · doc5.xml · nonDerivative · entry 1 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,693 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:19 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058649 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,791 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:23 UTC |
BISCHOFF WINFRIED F W SIRDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058653 · doc4.xml · nonDerivative · entry 1 BISCHOFF WINFRIED F W SIR · CIK 0001196150 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,727 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:25 UTC |
ESKEW MICHAEL LDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058656 · doc4.xml · nonDerivative · entry 1 ESKEW MICHAEL L · CIK 0001227734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,054 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:29 UTC |
FELDSTEIN MARTIN SDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058661 · doc4.xml · nonDerivative · entry 1 FELDSTEIN MARTIN S · CIK 0001236596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,733 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:34 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058670 · doc4.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,304 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:37 UTC |
GILMAN ALFRED GDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058674 · doc4.xml · nonDerivative · entry 1 GILMAN ALFRED G · CIK 0001225473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,941 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:41 UTC |
HORN KAREN NDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058678 · doc4.xml · nonDerivative · entry 1 HORN KAREN N · CIK 0001136550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,502 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:46 UTC |
MARRAM ELLEN RDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058680 · doc4.xml · nonDerivative · entry 1 MARRAM ELLEN R · CIK 0001234124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,733 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:49 UTC |
OBERHELMAN DOUGLAS RDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058682 · doc4.xml · nonDerivative · entry 1 OBERHELMAN DOUGLAS R · CIK 0001171770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,791 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:52 UTC |
PRENDERGAST FRANKLYN GDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058686 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,812 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 18:56 UTC |
SEIFERT KATHI PDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058690 · doc4.xml · nonDerivative · entry 1 SEIFERT KATHI P · CIK 0001222893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,516 Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 19:12 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 3,990 | $36.34 | $144,996.60 |
DisclosureSEC source: 0001209191-11-058697 · doc4.xml · nonDerivative · entry 2 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,383 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.